A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.

被引：6
|
作者：
Kaufman, Howard
Wang, Jiafeng
Curti, Brendan D.
Clark, Joseph
Ernstoff, Marc S.
Silk, Ann
Mehnert, Janice M.
Zloza, Andrew
Shih, Joe
McDermott, David F.
机构：
[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[3] Providence Canc Ctr, Earle A Chiles Res Inst, Portland, OR USA
[4] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[5] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[6] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps3095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3095
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of sequential temozolomide (TMZ) and high-dose bolus (HOB) IL-2 in patients with AJCC stage IV melanoma.
    Tarhini, A
    Agarwala, SS
    Gooding, W
    Cai, C
    Kirkwood, JM
    Stover, LL
    Blair, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 722S - 722S
  • [2] Phase II trial of sequential temozolomide (TMZ) and high-dose bolus (HDB) IL-2 in patients with metastatic melanoma.
    Agarwala, S. S.
    Tarhini, A. A.
    Kirkwood, J. M.
    Cai, C.
    Stover, L.
    Moschos, S.
    Gooding, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 462S - 462S
  • [3] CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
    Lau, Peter Kar Han
    Harris, Samuel John
    Eastgate, Melissa A.
    Kee, Damien
    Mant, Andrew
    Nott, Louise M.
    Gedye, Craig
    Inderjeeth, Andrisha Jade
    Underhill, Craig
    Weppler, Alison Margaret
    Wallace, Roslyn
    Lee, Belinda
    Au-Yeung, George
    Williams, Narelle
    Ospino, Daniel Ariza
    Gonzales, Louise
    Shackleton, Mark J.
    Lo, Serigne N.
    McArthur, Grant A.
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma
    Hodi, F. S.
    Friedlander, P. A.
    Atkins, M. B.
    McDermott, D. F.
    Lawrence, D. P.
    Ibrahim, N.
    Wu, X.
    Zhou, J.
    Giobbie-Hurder, A.
    Murphy, G.
    Hollman, T.
    Velazquez, E.
    Russell, S.
    Dipiro, P.
    Yap, J. T.
    Van den Abbeele, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma.
    Bowen, Randy Christopher
    Meek, Stephanie
    Williams, Matthew
    Grossmann, Kenneth F.
    Andtbacka, Robert Hans Ingemar
    Bowles, Tawnya Lynn
    Hyngstrom, John Robert
    Leachman, Sancy Ann
    Grossman, Douglas
    Holmen, Sheri L.
    VanBrocklin, Matthew W.
    Khong, Hung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma
    Geoerger, Birgit
    Bergeron, Christophe
    Gore, Lia
    Sender, Leonard
    Dunkel, Ira J.
    Herzog, Cynthia
    Brochez, Lieve
    Cruz, Ofelia
    Nysom, Karsten
    Berghorn, Elmer
    Simsek, Burcin
    Shen, Jun
    Pappo, Alberto
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 358 - 363
  • [7] Phase I trial of sequential decitabine plus high-dose interleukin-2 (HD IL-2) in patients with advanced melanoma.
    Gollob, J
    Thoreson, M
    Richmond, T
    Sciambi, C
    Bael, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 716S - 716S
  • [8] Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma
    Tarhini, A. A.
    Moschos, S. S.
    Schlesselman, J. J.
    Shope-Spotloe, J.
    Demark, M.
    Kirkwood, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Temozolomide (TMZ) and cisplatin (CDDP) combination in naive patients with stage IV melanoma. Definitive results of a phase II multicenter trial
    Tourani, J.
    Wiersbicka, E.
    Mourey, L.
    Guillot, B.
    Sassolas, B.
    Bedane, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase H trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma.
    Lutzky, J.
    Lawson, D. H.
    Enriquez-Nunez, Y.
    Gabrilovich, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345